XML 23 R11.htm IDEA: XBRL DOCUMENT
v3.19.1

Long-Term Investment | 12 Months Ended
--- | ---
Dec. 31, 2018
Long-Term Investment [Abstract] |
LONG-TERM INVESTMENT | 5. LONG-TERM INVESTMENT On December 24, 2018, the Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene’s Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for an aggregate number of 1,530,000 shares(See Note 4). As of December 31, 2018, the Company owns 23.90% common stock shares of Rgene, accounting for its equity interest using the equity method to its equity investment as prescribed in ASC 323, Investments—Equity Method and Joint Ventures (“ASC 323”). Equity method adjustments include the Company’s proportionate share of investee’s income or loss and other adjustments required by the equity method.
| (1) | The ownership percentages of the investee are listed as follows:
|  | Ownership percentage |  |  |
|  | December 31, |  |  | December 31, |  |  | Accounting
Name of related party |  | 2018 |  |  | 2017 |  |  | treatment
Rgene Corporation |  |  | 23.90 | % |  |  | N/A |  |  | Equity Method
| (2) | The extent the investee relies on the company for its business are summarized as follows:
Name of related party |  | The extent the investee relies on the Company for its business
Rgene Corporation |  | Collaborating with the Company to develop and commercialize drugs
| (3) | Long-term investment mainly consists of the following:
|  | December 31, |  |  | December 31, |
|  | 2018 |  |  | 2017 |
Equity Method Investments, net of impairment |  |  |  |  |  |  |  |
Rgene Corporation |  | $ | - |  |  |  | N/A |
Total |  | $ | - |  |  |  | N/A |
| (4) | Summarized financial information for the Company’s equity method investee, Rgene, is as follows:
Balance Sheets |  |  |  |  |  |
|  | December 31, 2018 |  |  | December 31, 2017 |
Current Assets |  | $ | 98,168 |  |  |  | N/A |
Noncurrent Assets |  |  | 14,779 |  |  |  | N/A |
Current Liabilities |  |  | 261,685 |  |  |  | N/A |
Shareholders’ Deficit |  |  | (148,738 | ) |  |  | N/A |
Statements of operation |  |  |  |  |  |
|  | For the Years Ended December 31, |
|  | 2018 |  |  | 2017 |
Net sales |  | $ | - |  |  |  | N/A |
Gross Profit |  |  | - |  |  |  | N/A |
Net loss |  |  | (120,065 | ) |  |  | N/A |
Share of loss from investments accounted for using the equity method |  |  | (549 | ) |  |  | N/A |
| (5) | Losses on Equity Investments
The components of losses on equity investments for each period were as follows:
|  | For the Years Ended December 31, |
|  | 2018 |  |  | 2017 |
Share of equity method investee losses |  | $ | (549 | ) |  |  | N/A |
Impairments |  |  | (2,549,451 | ) |  |  | N/A |
Total losses on equity investments |  | $ | (2,550,000 | ) |  |  | N/A |

X
- References No definition available. + Details
Name: | abvc_LongTermInvestmentTextBlock
Namespace Prefix: | abvc_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | abvc_LongtermInvestmentAbstract
Namespace Prefix: | abvc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration